Indian stocks: Visit www.stage2stocks.com →

Ascendis Pharma A/S

Stage 3 · Topping · week 5

As of Oct 22, 2026, Ascendis Pharma is in Stage 3, the topping phase, now in week 5 (since Sep 24, 2026). It closed at $242.99, 12.3% below its 52-week high and above its 200-day average, which is rising.

Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. More about the company

$242.99
+1.71% today
$16.0B · Large cap
Market Neutral — Building

Pro read

Pro

Our read

Topping: the uptrend is tiring

Setup score

—

Momentum

Steady

Edge

—

Is ASND early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S2 21w
S2 70w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S4 1w → S1 10w → S4 5w → S3 1w → S2 21w → S3 12w → S2 5w → S1 1w → S4 3w → S1 4w → S4 10w → S1 6w → S2 70w → S3 1w → S2 11w → S3 4w current
Total tracked: 165 weeks across 16 stage runs.

ASND among Biotechnology133rd of 591 by relative strength

All 591 →
Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#StockStageRS1M
1GTBPStage 2 · wk 799−22.3%
2IOVAStage 2 · wk 1899+38.8%
3SLSStage 3 · wk 499−1.5%
4MRNAStage 2 · wk 1799+11.3%
5TWSTStage 2 · wk 3999−14.5%
6KODStage 2 · wk 499+172.1%
7ERASStage 3 · wk 599+0.7%
8CLYMStage 3 · wk 399−15.8%
…133ASNDStage 3 · wk 571+8.9%
vs 52W High
-12.3%
$196.01 lo$277.18 hi
12.3% below 52W high, weakening from peak
The stock is rolling over from its 52-week high. In Stage 3 distribution, new long positions carry high risk.
Stage Maturity
Week 5
1w13w26w
Week 5, early distribution
How long this stock has been in Stage 3 distribution. Longer tops often precede deeper Stage 4 declines.
vs 200 DMA
2.5%
200 DMA: $236.99 · rising
Stock is losing its 200 DMA. Once lost, it confirms Stage 4 risk. This is a major red flag for existing holders.
Rel Volume
0.72x
vs 50-day avg
Volume spikes on down days during Stage 3 signal distribution, with institutions exiting. Stage analysis reads that as a warning against new long positions.
Trend Health
↓
Short-term trend rolling over
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
+8.9%
3M
-4.3%
6M
+8.0%
YTD
+13.9%
1Y
+21.1%
Scan Membership
Breakout Watch
Latest: 2025-02-18
9 appearances in last 60 days. First seen: 2019-02-11.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S3
Wk 5 · Vol 0.72x
2026-10-21S3
Wk 4 · Vol 0.69x
2026-10-20S3
Wk 4 · Vol 0.53x
2026-10-19S3
Wk 4 · Vol 1.75x
2026-10-16S3
Wk 4 · Vol 0.94x
2026-10-15S3
Wk 4 · Vol 0.56x
2026-10-14S3
Wk 3 · Vol 1.38x
2026-10-13S3
Wk 3 · Vol 0.82x
2026-10-12S3
Wk 3 · Vol 0.93x
2026-10-09S3
Wk 3 · Vol 1.14x
2026-10-08S3
Wk 3 · Vol 1.31x
2026-10-07S3
Wk 2 · Vol 1.17x
Moving averages & range
50 DMA
$242.65
200 DMA
$236.99
52W High
$277.18
52W Low
$196.01
5D Low
$225.25
Resistance levels (recent highs)
20d High
$242.99
60d High
$271.12
120d High
$277.18
250d High
$277.18
Next resistance
+11.6%
to 60d High
P/E (TTM)
18.6
Forward 22.5
ROE
+118.8%
Profit margin +70.8%
Dividend Yield
0.00%
P/B 9.9

Ascendis Pharma: quick answers

What stage is Ascendis Pharma in?

As of Oct 22, 2026, Ascendis Pharma (ASND) is in Stage 3, the topping phase. It entered Stage 3 on Sep 24, 2026 and is in week 5. What the four stages mean

Is Ascendis Pharma in an uptrend?

Its uptrend has stalled. Ascendis Pharma is in Stage 3, the topping phase that follows an advance. It trades 2.5% above its 200-day average, which is rising.

How far is Ascendis Pharma from its 52-week high?

Ascendis Pharma closed at $242.99 on Oct 22, 2026, 12.3% below its 52-week high of $277.18. Its 52-week low is $196.01.

How has Ascendis Pharma performed over the past year?

As of Oct 22, 2026, Ascendis Pharma is up 21.1% over the past year and up 13.9% so far in 2026.

Which sector and industry is Ascendis Pharma in?

Ascendis Pharma is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.